Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. Nelde A, et al. Among authors: gouttefangeas c. Nat Immunol. 2021 Jan;22(1):74-85. doi: 10.1038/s41590-020-00808-x. Epub 2020 Sep 30. Nat Immunol. 2021. PMID: 32999467
Problem solving for tumor immunotherapy.
Gouttefangeas C, Rammensee HG. Gouttefangeas C, et al. Nat Biotechnol. 2000 May;18(5):491-2. doi: 10.1038/75343. Nat Biotechnol. 2000. PMID: 10802611 No abstract available.
Towards patient-specific tumor antigen selection for vaccination.
Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanović S. Rammensee HG, et al. Among authors: gouttefangeas c. Immunol Rev. 2002 Oct;188:164-76. doi: 10.1034/j.1600-065x.2002.18815.x. Immunol Rev. 2002. PMID: 12445290 Review.
CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD, Stevanović S, Rammensee HG, Gouttefangeas C. Dittmann J, et al. Among authors: gouttefangeas c. Cancer Immunol Immunother. 2005 Aug;54(8):750-8. doi: 10.1007/s00262-004-0640-7. Epub 2004 Dec 22. Cancer Immunol Immunother. 2005. PMID: 15614528 Free PMC article.
113 results